Table 2 Appropriate patient selection for the 0.2 μg/day FAc intravitreal implant

• Uveitis expected to recur or persist for more than 2 years

• Treatment decisions are driven by ocular disease

• Non-responsive to, or intolerant of, standard therapy including systemic corticosteroids and various immunomodulatory therapeutic agents

• Sight-threatening disease

• Patients wishing to minimise the number of injections they receive (especially needle-phobic patients)

• EITHER no previous elevation of intraocular pressure in response to steroids OR willing to have medication or surgery if needed to reduce intraocular pressure

• Likely to comply with follow-up visits even when uveitis is quiet

• Patients with unilateral or bilateral disease

• Acute disease (as long-lasting treatment not required)

• Treatment decisions are NOT driven by ocular disease (e.g. if systemic treatment is still needed)

• Glaucoma

• Infectious uveitis

• Any other condition masquerading as non-infectious uveitis

• Not likely to comply with follow-up visits